Slide background

3 - 4 February 2015, London, UK

Slide background


Raise your corporate profile within an engaged audience of c-level executives.

Enquire today.



Lilly makes medicines that help people live longer, healthier, more active lives. Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity and respect for people.

Lilly has been operating in the UK since 1934 and is proud of its heritage in this country. London was host to our first office outside the United States and was closely followed by the first overseas manufacturing site, which opened in Basingstoke in 1939.



The Oxford Academic Health Science Network brings together the NHS, universities, business, patients and the public to promote best health for our population and prosperity for our region. Breaking down traditional organisational boundaries and building stronger relationships between industry, scientific and academic communities – coupled with better knowledge exchange – will bring lasting benefits as best practice is spread quickly and widely across the NHS.

The Oxford Academic Health Science Network area covers a population of 3.3 million living in Berkshire, Buckinghamshire, Milton Keynes, Oxfordshire and Bedfordshire. The NHS spends £5bn a year in our region and employs 65,000 people. The Oxford AHSN is also home to more than 500 companies and 12 Clinical Commissioning Groups, 4 Local Enterprise Partnerships, 12 Local authorities, 11 NHS Trusts and 9 Universities.



WilmerHale offers unparalleled legal representation across a comprehensive range of practice areas that are critical to the success of our clients. We practice at the very top of the legal profession and offer a cutting-edge blend of capabilities that enables us to handle deals and cases of any size and complexity. Today, businesses face greater scrutiny and more “bet the company” issues than ever before. With a practice unsurpassed in depth and scope by any other major firm, we have the ability to anticipate obstacles, seize opportunities and get the case resolved or the deal done—and the experience and know-how to prevent it from being undone.


Stratagem ipm

Stratagem IPM was formed in 1999 to respond to a developing need within the biotechnology industry for a clear and decisive strategic advice and management of intellectual property. Our service has been built on understanding and decisive action, not providing mere options and opinion and leaving the client to make the decision.

From the original biotechnology foundation, we have significantly expanded both resources and industry coverage. The company now has commercially trained intellectual property experts with first-hand experience of several industries.

Our experience, knowledge and expertise have proven effective wherever a company has a need for protecting or exploiting their intellectual property. We work as part of your business and team to meet the objectives you need from your intellectual property assets. Our services are applicable to all types of company from start-ups to multi-national corporations. Our services can evolve and develop as the client company grows.


James Cowper

With strategically placed offices in the South of England, membership of Kreston International and a global network of independent accountants and business advisers, James Cowper is ideally placed to provide informed local, national and international advice.

An integrated approach lies at the very heart of our business ethos. We consider all the angles when it comes to providing the widest levels of help, service and support for our clients, and apply the same approach to our people. We believe that a constructive work environment ultimately benefits everyone involved, including you.

This joined-up thinking extends beyond our own walls to the wider financial community. Our membership of Kreston International means that we’re well placed to help with overseas or inward investment.

Whatever your accounting or business advisory needs, our specialist teams work together on your behalf, placing a high value on sound communication. We understand the factors helping and hindering your immediate and long-term aspirations, and our shared vision is to help you succeed.


Marks & Clerk

Details to follow shortly.


Imperial Innovations

Imperial Innovations is focused on commercialising leading UK academic research sourced from the ‘golden triangle’ formed between Cambridge, Oxford and London.

Imperial Innovations is a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation, and investment.

Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.


Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners.

CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at


Edinburgh BioQuarter300x

Edinburgh Bioquarter

Edinburgh BioQuarter is an academic medical centre with a focus on interdisciplinary research and translational medicine, with particular strengths in regenerative medicine and connected health. The campus brings together clinicians, industrialists, patients, scientists, state-of-the-art pre-clinical and clinical research facilities, and an academic teaching hospital on one campus.

Extending to more than 100 acres, Edinburgh BioQuarter is a £600m joint venture between Scottish Enterprise, the University of Edinburgh and NHS Lothian. Once fully developed, the BioQuarter will offer up to 1.4m sq ft (130,063 sq m) of specialist accommodation for academic, commercial and healthcare activity.

The BioQuarter links a broad range of leading companies and research institutions, providing world class facilities with one-stop access to its unique combination of pre-clinical and clinical excellence.

The site currently boasts over 1,300 researchers, 120 academic clinicians, 960 inpatient beds, 15 on-site companies, an MHRA accredited Phase I clinical trials suite, a clinical research imaging centre housing CT/MRI/PET scanners, a GMP cell therapy manufacturing facility and an NHS clinical service laboratory.

There are also three MRC Centres on site specialising in Reproductive Health, Inflammation Research and Regenerative Medicine as well as a BHF Centre for Cardiovascular Medicine.

Future plans for the site include the construction of the Edinburgh Sick Children’s Hospital, which will provide an additional 600 patient beds and a paediatric clinical trials suite, and the Department of Clinical Neurosciences, both scheduled to open in 2017. Plans are also being taken forward for further university research institutes, a second multi-occupancy building for companies wishing to locate on the site as well as on site hotel and conferencing facilities.

The BioQuarter Commercialisation Team was established in 2010 to foster deeper links between academic researchers and the pharmaceutical industry through collaborative research; create new companies based on Edinburgh’s academic and clinical research base, and encourage a culture of commercialisation in the NHS and academia. It has since created more than 10 new life science businesses and successfully negotiated industrial collaborations in excess of £20 million. The team actively encourage the generation of new ideas and its Annual Innovation Competition has generated more than 150 novel product or business concepts.


Royal Holloway University of London

Royal Holloway, University of London can offer a wide range of opportunities to assist business with short term problems or long term strategic needs.Research and Enterprise helps business, the investment community and others to access our knowledge and expertise through contract research, consultancy, intellectual property licensing, and new business start-ups. We are always seeking opportunities to work with business in which our expertise can create new partnerships, accelerate the delivery of new products, processes or services or simply employ our unique combination of practical and leading-edge knowledge to enhance the performance of your business.



Intralinks® and the Biotech Journey

Biotech companies face a unique set of challenges. In IP development stages, Biotechs consume vast amounts of capital, so early investor trust is crucial.

As the IP moves to reality and approaches the market, IPO and finally M&A; activities become the focus; here again, trust is the key to success – in security of the IP, the value of the offering, and the solidity of the company.

Intralinks has built a reputation of trust in the Biotech community with a history of providing secure spaces and transactional tools for raising start-up capital; for keeping assets valuable and investor-ready; for taking companies public; and for exchanging critical, sensitive M&A; information.

Intralinks helps build Biotechs by protecting their most valuable assets along every step of the journey. We stand behind Biotechs, so their ideas can move forward.


Coulter Partners

Coulter Partners is an entrepreneurial organisation which understands leading edge science, technology and growth business models – the fastest growing of the top 10 search firms working on senior level, innovative life science roles, tapping the global expertise pool and working in a very different way from the traditional search firms.

We have one of the biggest and most experienced, dedicated sector teams based in Europe and North America, working globally to source candidates – with the approach of expert sector analysts involving our own PhD and industry experienced researchers and consultants.






Coté Orphan & ERA Consulting Group

Coté Orphan offers biopharmaceutical companies, private equity firms, and venture capital groups a comprehensive assessment of orphan products’ regulatory risk and potential opportunity. Coté has the unique combination of clinical and regulatory expertise to design an orphan development pathway tailored to meet the requirements of FDA, EMA, and other regulatory agencies. With a history of successful orphan designations and a deep knowledge of FDA and EMA orphan regulations, the Coté team can turn your product knowledge and innovation into a commercially available rare disease treatment.

The ERA Consulting Group is one of the longest established and most experienced consulting groups serving the biopharmaceutical industry.
Our emphasis is on consulting relating to quality, nonclinical and clinical aspects, both from the perspective of development strategy and regulatory requirements. Biopharmaceutical products and biomarkers are our particular speciality. ERA has the knowledge and experience to assist at all stages of product development, from conception to registration, and beyond.
Our expertise covers a wide range of products (around 400 to date), including products of recombinant DNA and hybridoma technology, synthetic peptides, conventional and advanced vaccines, advanced therapy medicinal products comprising gene therapy, somatic cell therapy and tissue-engineered products.


The BioHub Birmingham

The BioHub Birmingham is a fully serviced laboratory and vibrant innovation office designed to provide biomedical start-ups with access to affordable facilities and equipment. The first purpose-built facility in the UK; it is situated in a unique medtech community and provides access to Academic, Business and Clinical connections including University of Birmingham, QE Hospital, and new ITM.

The 4,500 sq.ft shared laboratory is fully managed, providing users with support and training. Flexible pricing enables tenants to manage their finances and focus on core activities.

The Birmingham Biomedical Innovation Hub is part funded by the European Regional Development Fund (ERDF).


Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst campus is a unique bioscience community created to provide small biotech and life sciences companies and start-ups with access to the expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies.

A key aim of Stevenage Bioscience Catalyst is to pioneer a culture of open-innovation that will place the UK bioscience sector at the forefront of worldwide biomedical discovery and deliver cutting edge healthcare solutions. Supported by Government, business, and the charitable sector, Stevenage Bioscience Catalyst campus offers a fertile environment for scientific innovation and commercial success.


London BioScience Innovation Centre

The London BioScience Innovation Centre (LBIC) provides a focus for life sciences activity in the UK capital, offering laboratory and office facilities of an exceptionally high standard and a professional front door that cannot fail to impress.

Owned by the prestigious Royal Veterinary College, LBIC is home to over 50 biotechnology and life science companies in central London, including small start-ups and more established players.

Our location is second-to-none; just a short walk from St Pancras International station and the site of the new Francis Crick Institute.

We attract biotechnology, life science product and diagnostic companies, contract research organisations, medical device companies and service providers.


Imperial College London Incubator

The Imperial Incubator is a hub for innovation and entrepreneurship, providing office and laboratory space for early-stage companies. The two-storey 24,000 foot Incubator facility contains 12 laboratories, 22 offices, meeting rooms and break-out areas. This state of the art premises is conveniently located in South Kensington, Zone 1, making it an ideal location for commuters.

Situated at the campus of Imperial College London, consistently among the highest ranked universities in the world, early stage businesses are able to take advantage of being in close proximity to eminent scientists and experts in technology.Learn more about the Incubator and what it offers

The Incubator contains a true entrepreneurial community who share the experience of developing technology business. Imperial Innovations runs a programme of seminars and events at the Incubator, designed specifically for entrepreneurs and inventors. Read more to find out about what the Incubator offers start ups.


BioCity Nottingham

BioCity Nottingham is an address with international credibility and prestige.

Established in 2003 BioCity was one of the first Bioscience incubators offering state-of-the-art laboratories and commercial office space to let/rent, alongside business support and services to early stage companies in the life sciences sector.

Due to the success of BioCity it has become one of the largest Bioscience incubators in Europe, with locations in Scotland, Cheshire and recently on the Alliance Boots site in Nottingham.
This growth has been driven by the success of the many businesses nurtured by the BioCity environment, making it an international hub for entrepreneurial activity in the life sciences.


Knowledge Transfer Network UK

Connecting people who accelerate innovation.

The KTN is the UK’s innovation network. We bring together businesses, entrepreneurs, academics and funders to develop new products, processes and services.

We can help you develop ideas, expertise and technologies, that have the potential to be world-beating products processes and services. Central to what we do is the initiation and building of collaborations.



Consilium Strategic Communications

Consilium Strategic Communications is a global leader in providing trusted, healthcare-focused strategic IR and financial PR counsel to corporations, Boards, senior decision makers and executives.

From offices in Europe, the USA and Asia, Consilium Strategic Communications’ senior team provides cross-border comprehensive financial and corporate healthcare communications advice to some of the world’s most prominent corporations around-the-clock.


Instinctif Partners

We combine strategic and creative thinking to help our clients engage with and influence their key stakeholders. We understand the power of reputation in a world where reputations are vulnerable.

Connecting financial communications to corporate affairs to public policy and employee engagement with the very best in creativity, story telling and digital capability we help our clients to develop a joined up story. Truly international in outlook and reach, we are as connected to our clients and their audiences as we are to each other.



Sciad is a marketing communications agency that works with businesses in healthcare, life science, the environment and other science and technology-based sectors. We use integrated marketing communications to drive up reputations, connecting with the audiences that matter most, by maximising the power of the web and the media including Public Relations, Social Media, Search Engine Optimisation, Paid Search, Websites and Mobile marketing.

The Sciad team are experts in online marketing communications and have extensive experience of working with life science and healthcare companies.


Zyme Communications

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

With clients across Europe and the USA, Zyme is focused on supporting companies to raise their profile and generate interest from commercial leads, investors and partners. With an international network of life science trade media contacts and a strong technical understanding, Zyme is committed to providing real value from objective-led communications, flexibility to suit your strategy and budget and an experienced senior team, specialists in life science PR and marketing.

Media Partner


BioCentury Publications, Inc. is recognized as the leading provider of value-added information, analysis and data essential to the development and sustainability of life science ventures.

Media Partner

Biopharm Insight

BioPharm Insight is Infinata’s flagship intelligence solution for the global healthcare markets. With its dedicated team of more than a dozen investigative journalists, BioPharm Insight delivers forward-looking, exclusive intelligence to its subscribers every day. BioPharm Insight’s editorial team covers life sciences from offices in New York and London. For more information about BioPharm Insight visit the website:

Media Partner

Current Partnering

Current Partnering is the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.
Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.

Our reports cover all aspects of partnering best practice. Further details for each report can be viewed online at:

Media Partner

Drug Discovery Today

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

Media Partner

European Pharmaceutical Review

European Pharmaceutical Review is the leading bi-monthly publication for information on technologies in drug discovery and manufacturing. Every issue offers a high level of technical and business contributions from the world's leading pharmaceutical companies and academic institutions, coupled with new and exciting features including interviews, updates and profiles.

Media Partner

IPI - International Pharmaceutical Industry

IPI – was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Edited by our carefully selected editorial advisory panel, and extensive research network, IPI provides a proven supportive means of communication to the pharmaceutical, bio pharmaceutical, nutraceutical and medical devices industry the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies which will enable them to be more efficient, bring products to market faster, reduce cost and make healthcare accessible to all.

We have established a strong presence in the US, Central Europe, Middle East, Latin America, Eastern Europe, Asia and Africa which are becoming increasingly important to the way the industry is moving forward in areas of Research and Development, Trials, Manufacturing and Technology Transfer.

Media Partner

IP Pro Lifesciences

From private practice life sciences groups, to multinational pharmaceutical companies, university labs and venture capitalists, IPPro Life Sciences has something for everyone with an interest in intellectual property and the legal implications for the life sciences

Media Partner


Pharmalicensing ( is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.

Media Partner


We offer a comprehensive range of transaction related healthcare advisory services. An unrivalled track record of successful transaction outcomes, strategic insight, specialist knowledge and experience within our industry makes us uniquely placed to support your business in all aspects of transactions from strategy to getting the deal done. Our experience is gained from working with clients in 38 countries and conducting more than 600 assignments.

Media Partner


PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

Media Partner

Scrip Intelligence

SCRIP Intelligence is the leading source of pharmaceutical and biotech news, analysis and data, providing expert knowledge on global pharma issues from M&A; deals and business to R&D;, drug delivery and clinical trials. SCRIP analyses significant facts, trends and predictions to save you time and give you invaluable insight.

Biotech and Money Ltd. The Euston Office, One Euston Square, 40 Melton St, London, NW1 2FD. Call us: +44 (0) 203 574 4619